Blog

Instem, a global leader in SaaS solutions for life sciences R&D, today announced a 5-year extension of its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA). 

In this blog, we answer a number of recurring questions about validation, reproducibility, governance, and risk while using R for clinical data analytics.

Unifying Science and Safety to Navigate the Iterative Path of Lead Optimization

In this blog, we discuss the need to outsource CTT work for EU CTR, Policy 0070 & HC Submissions as pharma cuts back on internal CTT teams.

Discover how Instem’s Advance™, Predict™, and BioRails® accelerate early-stage drug discovery by unifying in silico insights, experimental data, and streamlined workflows.

With integrated, insight‑driven platforms that cut through data complexity and eliminate fragmented workflows, Instem empowers researchers to reduce risk, boost efficiency, and accelerate the journey from discovery to IND submission.

Modernised Headquarters Underscores Instem’s Commitment to Innovation, Customer Excellence and the Local Region

NAMs have the potential to deliver more efficient safety assessments, enabling faster and more confident development decisions while also supporting more ethical drug development.

Compliance Builder 12 introduces several enhancements that directly support stronger compliance control and faster issue detection, helping organizations prevent minor issues from becoming major CAPA violations.